Preview

Epilepsy and paroxysmal conditions

Advanced search

CLINICAL AND NEUROLOGICAL MANIFESTATIONS OF DRUG-RESISTANT EPILEPSY AND OPTIMIZATION OF PATIENT TREATMENT

https://doi.org/10.17749/2077-8333.2019.11.1.46-52

Full Text:

Abstract

Aim – to study the clinical and neurological manifestations in patients with drug-resistant epilepsy and optimize the therapy. Materials and methods. Fifty patients with drug-resistant epilepsy were examined. Of these, 28 were females and 22 were males; their average age was 32.6±11.4 years. All patients had true pharmacoresistant epilepsy, i. e., the seizures occurred on the background of adequate polytherapy with anticonvulsants; the use of anticonvulsants had no effect on the course of the disease. All patients underwent clinical and neurological examination. The patients were blindly divided into two therapeutic groups: the main group consisted of 25 patients who were prescribed with the combined therapy, which included a biologically active polypeptide at a dose of 10 mg/day for 20 days with a subsequent transition to hopantenic acid (500 mg twice a day for 2 months). The second group did not receive these drugs. For the anticonvulsant therapy, both groups received the combinations of valproic acid (30 mg/kg at two daily doses) and carbamazepine (5 mg/kg at three daily doses). The significance of differences was determined by the paired and unpaired Student’s t-test. The differences were considered statistically significant at p <0.05. Results. The data on the occurrence of subjective and focal neurological symptoms indicated the prevalence of complaints characteristic of general cerebral symptoms in the form of headaches, dizziness, as well as subjective symptoms of cerebral asthenia. In addition, some patients complained of short-term memory impairments. In most cases, drug-resistant epilepsy developed on the background of organic brain damage. In 87.2±6.9% of cases, we encountered a Chvostek sign indicating an increased excitability of the nervous system. Both groups of patients showed positive yet different clinical dynamics: the number of seizures decreased in 40% of patients taking the polypeptide regulator and hopantenic acid, and in 28% of patients in the comparison group (p<0.05). Conclusion. In order to optimize the anticonvulsant therapy, it is recommended to prescribe a combination of valproate and carbamazepine; to increase the efficacy of the combined therapy it is recommended to add the polypeptide regulator and hopantenic acid.

About the Authors

Yo. N. Madjidova
Tashkent pediatric medical institute
Uzbekistan

MD, PhD, Head of the Department of Neurology, Pediatric Neurology and Medical Genetics TashPMI, Professor, Deputy Chair of the Association of Neurologists of Uzbekistan

243 Bogishamol Str., Tashkent 100140, Yunusabad district, Uzbekistan



A. A. Solikhzoda
Tashkent pediatric medical institute
Uzbekistan

MSc, Department of Neurology, Pediatric Neurology and Medical Genetics

243 Bogishamol Str., Tashkent 100140, Yunusabad district, Uzbekistan



Kh. N. Maksudova
Tashkent pediatric medical institute
Uzbekistan

MD, PhD, Associate Professor at the Department of Neurology, Pediatric Neurology and Medical Genetics

243 Bogishamol Str., Tashkent 100140, Yunusabad district, Uzbekistan



References

1. Tujchibaeva N. M., Tujchibaeva N. M., Karimov X. Ya. Pharmacogenetic aspects of pharmacoresistant epilepsy in Uzbekistan. Nevrologiya. 2014; 60 (4): 35-37. (In Russ.).

2. Tujchibaeva N. S., Karimov X. Ya. Molecular genetic aspects of anti-epileptic therapy in patients with pharmacoresistant epilepsy. Nevrologiya. 2013; 2: 11-14. (In Russ.).

3. Xalilova A. Eh., Sharipova N. R., Svistunova O. V., Fajzullaev B. F. Pharm acoresistant epilepsy in children in the structure of epileptic syndromes. Nevrologiya. 2010; 4: 46-48. (In Russ.).

4. Zenkov L. R. Pharmacological treatment of epilepsy. Russkij medicinskij zhurnal. 2000; 8: 411-417. (In Russ.).

5. To study of the epidemiology of epilepsy with mental disorders (according to the materials of the Leningrad region). Russian epileptology in the modern world (to the 100th anniversary of the Russian Antiepileptic League): Congress materials with international participation. St. Petersburg, February 17-19, 2010; 57-60. (In Russ.).

6. Tujchibaeva N. M., Islamova Sh. A., Shigakova L. A., Otaeva N. T. Drugresistant epilepsy. Mechanisms and causes. Infekciya, immunitet i farmakologiya. 2014; 4: 123-129. (In Russ.).

7. Zenkov L. R., Yaxno N. N., Usacheva E. L. Depakin Chrono in the treatment of epilepsy resistant to other drugs. Nevrologicheskij zhurnal. 2000; 5: 39-42. (In Russ.).

8. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G. D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007; 48 (7): 1308-17.

9. Zenkov L. R. Clinical electroencephalography with elements of epileptology. Taganrog. 1996; 357 s. (In Russ.).

10. Aldenkamp A. P., De Krom M., Reijs R. Newer antiepileptic drugs and cogni- tive issues. Epilepsia. 2012; 44 (4): 21-29.

11. Berg M. J., Gross R. A., Tomaszewski K. J., et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. 2008; 71: 525-30.


For citation:


Madjidova Y.N., Solikhzoda A.A., Maksudova K.N. CLINICAL AND NEUROLOGICAL MANIFESTATIONS OF DRUG-RESISTANT EPILEPSY AND OPTIMIZATION OF PATIENT TREATMENT. Epilepsy and paroxysmal conditions. 2019;11(1):46-52. (In Russ.) https://doi.org/10.17749/2077-8333.2019.11.1.46-52

Views: 59


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)